Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 13/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | PPIA | P62937 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079939 | 0.93 | DHODH (0.41) | PTGER1MCL1DHODH | |
| SCHEMBL6593354 | 0.91 | PTGER1 (0.50) | PTGER1CYP2C9MCL1 | |
| SCHEMBL6080254 | 0.85 | PTGER1 (0.41) | PTGER1CYP2C9DHODH | |
| SCHEMBL6079994 | 0.84 | DHODH (0.46) | PTGER1MCL1DHODHGPR34 | |
| SCHEMBL6593657 | 0.83 | PTGER1 (0.47) | PTGER1MCL1 | |
| SCHEMBL6079213 | 0.80 | ERN1 (0.48) | PTGER1CYP2C9MCL1DHODH | |
| SCHEMBL6080651 | 0.80 | PTGER1 (0.42) | PTGER1MCL1 | |
| SCHEMBL6081081 | 0.79 | PTGER1 (0.45) | PTGER1CYP2C9DHODH | |
| SCHEMBL6080066 | 0.76 | PTGER1 (0.43) | PTGER1CYP2C9MCL1PPIA | |
| SCHEMBL6080347 | 0.76 | MRGPRX4 (0.42) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | PTGER1 1819/4885CYP2C9 199/4885MCL1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.